Market revenue in 2023 | USD 1,483.7 million |
Market revenue in 2030 | USD 2,736.4 million |
Growth rate | 9.1% (CAGR from 2023 to 2030) |
Largest segment | Anti-vegf agents |
Fastest growing segment | Gene & Cell Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti-Allergy, Anti-VEGF agents, Anti-inflammatory, Anti-glaucoma, Gene & Cell Therapy |
Key market players worldwide | Pfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ophthalmic drugs market will help companies and investors design strategic landscapes.
Anti-vegf agents was the largest segment with a revenue share of 32.62% in 2023. Horizon Databook has segmented the Canada ophthalmic drugs market based on anti-allergy, anti-vegf agents, anti-inflammatory, anti-glaucoma, gene & cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The Canada ophthalmic drugs market is expected to grow at a steady rate. According to the Canadian Institute for Health Information, healthcare expenditure in the nation is expected to reach USD 331 billion, representing 13.2% of the nation’s GDP, in 2022.
An increase in awareness programs undertaken by various organizations is anticipated to propel market growth in Canada. In addition, various factors, such as increasing funds for R&D, especially structurebased drug designing, and technological innovations in ophthalmic drug technologies, are expected to create significant opportunities for growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada ophthalmic drugs market , including forecasts for subscribers. This country databook contains high-level insights into Canada ophthalmic drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account